BC Innovations | Apr 14, 2016
Distillery Therapeutics

Therapeutics: Solute carrier family 22 organic cation transporter member 2 (SLC22A2; OCT2); POU class 2 associating factor 1 (POU2AF1; BOB1)

Cancer INDICATION: B cell lymphoma Patient sample and cell culture studies suggest inhibiting SLC22A2 or POU2AF1 could help treat diffuse large B cell lymphoma (DLBCL). Genetic sequencing of tumor samples from 207 DLBCL patients identified...
BC Week In Review | Jun 1, 2015
Company News

Leiden University, Bellicum deal

The university granted Bellicum exclusive, worldwide rights to high-affinity T cell receptor (TCR) products targeting solid tumors expressing the preferentially expressed antigen in melanoma (PRAME) . Bellicum plans to start Phase I/II testing of the first...
BC Week In Review | Jul 22, 2013
Company News

General Electric sales and marketing update

General Electric's Clarient Diagnostic Services Inc. company launched the Hodgkin Lymphoma Profile by MultiOmyx test to aid in the diagnosis of CD30-positive lymphoma with difficult morphology or otherwise insufficient tissue. The test uses Clarient's MultiOmyx...
Items per page:
1 - 3 of 3